Join AlphaMaven

The Home Of Alternative Investments

Register For Free Learn More Create Investment Listing

Most Visited Alternative Investment Industry Website. Over 50,000 visitors per month

Alternative Investment Posts

Webinar: AyuVis Helping Pre-Term Babies Grow Into Normal, Healthy Children
Venture Capital AlphaMaven Views: 1

To register for the webinar click here.

Each year as many as 15,000 babies in the U.S. develop Bronchopulmonary Dysplasia (BPD), a condition that is the leading cause of death in premature infants. 

AyuVis is a biopharmaceutical company dedicated to helping pre-term babies grow into normal, healthy adults. They have developed a first-in-class, small molecule, preventative therapeutic for BPD that has shown great promise in pre-clinical testing thanks to its dual anti-inflammatory and anti-mic


Member Posts:

Most popular| Most recent
Golden Eagle Growth Fund - AlphaMaven Performance Report
Hedge Fund Golden Eagle Hypergrowth Strategy #Investment Update
AlphaMaven Crypto Traders Index
Crypto AlphaMaven Crypto Traders Index #Investment Update
AlphaMaven Cannabis Index
Cannabis AlphaMaven Cannabis Index #Investment Update
Gates Capital Management's ECF Value Fund - AlphaMaven Performance Report
Hedge Fund ECF Value Fund, L.P. #Investment Update
Cooper Creek Partners (Class A) - AlphaMaven Performance Report
Hedge Fund Cooper Creek Partners LLC (Class A) #Investment Update
Lyons Small Cap Value Fact Sheet - Q1 2025
Hedge Fund Lyons Small Cap Value Portfolio #Investment Update
Tulip Trend Fund (USD C) Factsheet_April 2025
Managed Futures Tulip Trend Fund UCITS #Newsletter
Tulip Trend Fund UCITS (EUR A) Factsheet_April 2025
Managed Futures Tulip Trend Fund UCITS #Newsletter
How RIAs Can Access Better Private Equity
Private Equity Chad Brown, CFA, CAIA #Video #Podcast Episode
Exome Emerging Markets Healthcare Partners Strategy Posts Its April 2025 Results
Hedge Fund Emerging Markets Healthcare Partners Strategy #Presentation
Exome Worldwide Healthcare Partners Posts Its April 2025 Performance
Hedge Fund Worldwide Healthcare Partners #Presentation
Exome Asset Management's Emerging Markets Healthcare Partners Strategy - AlphaMaven Pe ...
Hedge Fund Emerging Markets Healthcare Partners Strategy #Investment Update
Exome Asset Management's Worldwide Healthcare Partners - AlphaMaven Performance Report
Hedge Fund Worldwide Healthcare Partners #Investment Update
Oxeye Hedged Income Option Strategy - AlphaMaven Performance Report
Hedge Fund Oxeye Hedged Income Option Strategy #Investment Update
Oxeye Buyback Option Premium Strategy 7.5X (BOPS 7.5X) - AlphaMaven Performance Report
Hedge Fund Oxeye Buyback Option Premium Strategy 7.5x Leveraged (BOPS 7.5X) #Investment Update
SDI Partners - Accredited Partner Fund - AlphaMaven Performance Report
Hedge Fund SDI Partners - Accredited Partner Fund #Investment Update
Oxeye Buyback Option Premium Strategy (BOPS 5x) - AlphaMaven Performance Report
Hedge Fund Oxeye Buyback Option Premium Strategy (BOPS 5X) #Investment Update
AlphaMaven Managed Futures Index
Managed Futures AlphaMaven Managed Futures Index #Investment Update
AlphaMaven Real Estate Index
Real Estate AlphaMaven Real Estate Index #Investment Update
AlphaMaven Private Equity Index
Private Equity AlphaMaven Private Equity Index #Investment Update
FREE NEWSLETTER (140K+ Subscribers)
View Member Posts Listings
SPONSORED BY
Be Seen - Advertise With Us
Click to Discuss
FEATURED MEMBER POSTS
Andrea Alms Video:  Money In Motion 149 - Pediatric Rare Disease Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 152 - Tariffs Pharma/Biotech Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 151 - Ozempic Impact & GLP-1 Receptor Agonist Market Update
- posted by: BrookDell Partners
Exome Emerging Markets Healthcare Partners Strategy Posts Its April 2025 Results
- posted by: Emerging Markets Healthcare Partners Strategy
Andrea Alms Video:  Money In Motion 153 - FDA Staff Cuts - Biotech Regulatory Delays Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 150 - Gene Therapy Adeno-Associated Virus (AAV)
- posted by: BrookDell Partners
Exome Worldwide Healthcare Partners Posts Its April 2025 Performance
- posted by: Worldwide Healthcare Partners
Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates

Subscribe to our FREE DAILY newsletter

Please Select Industry Primary Role*
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.